title: Complete remission of recurrent and refractory uterine epithelioid leiomyosarcoma using weekly administration of bevacizumab and temozolomide.
authors: Masashi
authors: M
authors: Takano
authors: Yoshihiro
authors: Y
authors: Kikuchi
authors: Nobuyuki
authors: N
authors: Susumu
authors: Kazuya
authors: K
authors: Kudoh
authors: Tsunekazu
authors: T
authors: Kita
authors: Hiroko
authors: H
authors: Kouta
authors: Tomoko
authors: T
authors: Goto
authors: Kenichi
authors: K
authors: Furuya
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000068258:Bevacizumab; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000517:prevention & control; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000517:prevention & control; D012074:Remission Induction / Q000379:methods; D000077204:Temozolomide; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D018906:Antineoplastic Agents, Alkylating; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide